Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before ...

In a report released today, Brandon Couillard from Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), with a price target ...

Bruker’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Bruker (BRKR) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

timsTOF was engineered by Bruker experts as an open platform to accelerate the adoption of ion mobility-mass spectrometry analysis across research applications. All that is missing are your ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...

Merit Financial Group LLC acquired a new stake in shares of Bruker Co. (NASDAQ:BRKR – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 5,115 shares of the medical ...

Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share.

Integration with Bruker’s MALDI Imaging methods enable multimodal imaging to characterize tissues with enhanced analytical depth. The LUMOS II ILIM can also be used for rapid pharmaceutical ...